DNAH8-AS1: A Potential Drug Target and Biomarker (G100131047)

Target Name: DNAH8-AS1

NCBI ID: G100131047

DNAH8-AS1

Other Name(s): DNAH8 antisense RNA 1

DNAH8-AS1: A Potential Drug Target and Biomarker

DNA damage has been linked to numerous diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Damaged DNA can lead to the formation of mutations, which can result in the activation of oncogenes and the progression of disease. The discovery of DNAH8-AS1, a protein that is expressed in various tissues and is involved in DNA repair processes, has raised the possibility that it may be a drug target or biomarker for various diseases.

DNAH8-AS1: Structure and Function

DNAH8-AS1 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, brain, and peripheral blood. It is composed of a N-terminal transmembrane domain, a coiled-coil region, and a C-terminal T-loop domain. The transmembrane domain is responsible for the protein's ability to interact with various signaling molecules, while the coiled-coil region allows for the protein's flexibility and stability. The T-loop domain is involved in the protein's stability and functions as a binding site for various DNA repair factors.

DNAH8-AS1 plays a crucial role in DNA repair processes. When DNA is damaged, DNAH8-AS1 is recruited to the site of the damage and helps to repair the damage by interacting with the DNA repair machinery. This interaction between DNAH8-AS1 and DNA repair factors highlights the protein's potential as a drug target or biomarker for diseases that are characterized by DNA damage.

Potential Therapeutic Applications

The discovery of DNAH8-AS1 has led to the possibility of using it as a drug target or biomarker for various diseases. One potential therapeutic application for DNAH8-AS1 is the treatment of cancer. DNAH8-AS1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. By targeting DNAH8-AS1, researchers may be able to inhibit the growth of cancer cells and potentially lead to a more effective treatment for these diseases.

Another potential application for DNAH8-AS1 is the treatment of neurodegenerative disorders. DNAH8-AS1 has been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. By targeting DNAH8-AS1, researchers may be able to develop new treatments for these disorders that can slow the progression of disease and potentially improve quality of life.

DNAH8-AS1 has also been shown to be involved in the development and progression of cardiovascular diseases. When DNA is damaged in the cardiovascular system, the formation of mutations can lead to the activation of oncogenes and the progression of disease. By targeting DNAH8-AS1, researchers may be able to develop new treatments for cardiovascular diseases that can slow the progression of disease and improve patient outcomes.

Conclusion

In conclusion, DNAH8-AS1 is a protein that is expressed in various tissues and is involved in DNA repair processes. The discovery of DNAH8-AS1 has raised the possibility that it may be a drug target or biomarker for various diseases. Further research is needed to fully understand the functions of DNAH8-AS1 and its potential as a therapeutic agent.

Protein Name: DNAH8 Antisense RNA 1

The "DNAH8-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAH8-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets